Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 18.9%, EPS grew 81.3%, free cash flow grew 19.1% and total debt fell 25.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow AUPH
Aurinia Pharmaceuticals Inc (AUPH) EV/Sales
As of 16 October 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a EV/Sales of 5.6×. Over the past ten years it has ranged from 1.6× (December 2022) to 13,487× (October 2020); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.4× | 51.63% |
| FY2024 | 4.2× | (24.75%) |
| FY2023 | 5.6× | 62.57% |
| FY2022 | 3.4× | (93.75%) |
| FY2021 | 54.8× | 120.35% |
| FY2020 | 24.9× | (99.50%) |
| FY2019 | 4,965× | 408.19% |
| FY2018 | 977× | 104.61% |
| FY2017 | 477× | 128.11% |
| FY2016 | 209× | (23.13%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.8× | 6.16% |
| Mar 2026 | 5.5× | (13.89%) |
| Dec 2025 | 6.4× | 45.47% |
| Sep 2025 | 4.4× | 28.09% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 1.1× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| NVAX Novavax, Inc. compare | 3.4× |
| AUPH Aurinia Pharmaceuticals Inc | 5.6× |
| VRDN Viridian Therapeutics, Inc. compare | 18.6× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 23.7× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)